Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases
— Hundreds of de novo patentable psychedelic-based compounds created through discovery program— — Company plans to announce lead molecule in first quarter of 2022 — Vancouver, BC – November 30, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for…
